Russell Investments Group Ltd. Lowers Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Russell Investments Group Ltd. reduced its position in shares of Hims & Hers Health, Inc. ( NYSE:HIMS – Free Report ) by 11.

3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,382 shares of the company’s stock after selling 17,426 shares during the quarter. Russell Investments Group Ltd.



’s holdings in Hims & Hers Health were worth $3,322,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds have also bought and sold shares of HIMS. Crewe Advisors LLC bought a new position in Hims & Hers Health in the fourth quarter worth approximately $28,000.

Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter.

Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc.

raised its position in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc.

now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter.

Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth $38,000. 63.

52% of the stock is owned by institutional investors. Insiders Place Their Bets In other Hims & Hers Health news, insider Soleil Boughton sold 3,236 shares of the company’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $28.

72, for a total value of $92,937.92. Following the sale, the insider now directly owns 162,898 shares of the company’s stock, valued at approximately $4,678,430.

56. This represents a 1.95 % decrease in their ownership of the stock.

The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $28.

50, for a total value of $330,058.50. Following the sale, the chief financial officer now directly owns 118,960 shares in the company, valued at $3,390,360.

This represents a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here .

In the last ninety days, insiders sold 806,811 shares of company stock valued at $30,999,332. 17.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance Hims & Hers Health ( NYSE:HIMS – Get Free Report ) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.

09 by $0.02. The firm had revenue of $481.

14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.

97% and a net margin of 8.19%. As a group, equities research analysts expect that Hims & Hers Health, Inc.

will post 0.29 earnings per share for the current year. Analysts Set New Price Targets A number of brokerages have commented on HIMS.

Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th.

Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $42.00 to $60.

00 in a research note on Tuesday, February 18th. Piper Sandler upped their price target on Hims & Hers Health from $24.00 to $35.

00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Finally, Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.

00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.

com, the company currently has an average rating of “Hold” and an average target price of $38.25. Check Out Our Latest Research Report on Hims & Hers Health Hims & Hers Health Company Profile ( Free Report ) Hims & Hers Health, Inc operates a telehealth consultation platform.

It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. Read More Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. ( NYSE:HIMS – Free Report ). Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.

com's FREE daily email newsletter ..